

Bibliografia

- [1] Saika K, Sobue T. Cancer statistics in the world. *Gan To Kagaku Ryoho* 2013 Dec; 40 (13): 2475-80.
- [2] Hartley LC, Evans E, Windsor CJ. Factors influencing prognosis in gastric cancer. *Aust N Z J Surg* 1987 Jan; 57 (1): 5-9.
- [3] Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat* 2008 Feb; 107 (3): 309-30.
- [4] Yoshimi A, Kojima S, Hirano N. Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations. *Paediatr Drugs* 2010; 12 (1): 11-21.
- [5] Sonmez M, Erkut N, Ucar F, Buruk K, Cobanoglu U, Bahce M, Ural AU. Familial Hodgkin's lymphoma from the perspective of HLA. *Intern Med* 2010; 49 (6): 607-10.
- [6] Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif* 2003 Jun; 36 (3): 131-49.
- [7] McDonald ER 3rd, El-Deiry WS. Cell cycle control as a basis for cancer drug development. *Int J Oncol* 2000 May; 16 (5): 871-86.
- [8] Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. *Proc Natl Acad Sci USA* 2012 Sep 18; 109 (38): 15101-8.
- [9] Chwalek K, Bray LJ, Werner C. Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. *Adv Drug Deliv Rev* 2014 May 9.
- [10] Mihalache A, Rogoveanu I. Angiogenesis Factors Involved in the Pathogenesis of Colorectal Cancer. *Curr Health Sci J* 2014 Jan; 40 (1): 5-11.
- [11] Stockmann C, Schadendorf D, Klose R, Helfrich I. The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling. *Front Oncol* 2014 Apr 8; 4: 69.
- [12] Chen YQ. Cancer and Metastasis Reviews. Introduction. *Cancer Metastasis Rev* 2013 Jun; 32 (1-2): 3-4.
- [13] Sciacovelli M, Gaude E, Hilvo M, Frezza C. The metabolic alterations of cancer cells. *Methods Enzymol* 2014; 542: 1-23.
- [14] Iurlaro R, León-Annicchiarico CL, Muñoz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. *Methods Enzymol* 2014; 542: 59-80.
- [15] Bos JL. Ras oncogenes in human cancer: a review. *Cancer Res* 1989 Sep 1; 49 (17): 4682-9.
- [16] Regala RP, Weems C, Jamieson L, Koor A, Edell ES, Lohse CM, Fields AP. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. *Cancer Res* 2005 Oct 1; 65 (19): 8905-11.
- [17] Pereira CB, Leal MF, de Souza CR, Montenegro RC, Rey JA, Carvalho AA, Assumpção PP, Khayat AS, Pinto GR, Demachki S et al. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. *PLoS One* 2013; 8 (3): e60576.
- [18] Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. *Mammary Gland Biol Neoplasia* 2001 Oct; 6 (4): 393-406.
- [19] Clerico L, Mancuso T, Noonan D, Albin A. Oncosuppressor genes: mechanisms of inactivation for the retinoblastoma gene and p53. *Boll Soc Ital Biol Sper* 1993 Dec; 69 (12): 725-34.
- [20] Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. *Mol Oncol* 2012 Aug; 6 (4): 458-72.
- [21] Kassiotis G. Endogenous retroviruses and the development of cancer. *J Immunol* 2014 Feb 15; 192 (4): 1343-9.
- [22] Botelho MC, Machado JC, da Costa JM. Schistosoma haematobium and bladder cancer: what lies beneath? *Virulence* 2010 Mar-Apr; 1 (2): 84-7.
- [23] Colquhoun BP, Visvanathan K. Adenocarcinoma of the pancreas associated with Clonorchis sinensis infection. *CMAJ* 1987 Jan 15; 136 (2): 153-4.
- [24] Eastmond DA, Keshava N, Sonawane B. Lymphohematopoietic cancers induced by chemicals and other agents and their implications for risk evaluation: An overview. *Mutat Res Rev Mutat Res* 2014 Apr 13.
- [25] Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J. Colorectal cancer and immunity: what we know and perspectives. *World J Gastroenterol* 2014 Apr 14; 20 (14): 3738-50.
- [26] Fallon MT. Neuropathic pain in cancer. *Br J Anaesth* 2013 Jul; 111 (1): 105-11.
- [27] UICC, *Manuale di Oncologia Clinica*, Minerva Medica, 2007.
- [28] Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer

- therapeutics. *Pharmgenomics Pers Med* 2014 Feb 5; 7: 53-64.
- [29] Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K, Takano M, Furuya K, Sato S, Itamochi H, Tsubamoto H, Hasegawa K, Terao K, Otsuki T, Kuritani K, Ito K. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. *Support Care Cancer* 2014 May 14.
- [30] Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: natural history, prevention and treatment. *Mol Clin Oncol* 2014 May; 2 (3): 337-340.
- [31] Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? *Nutr Metab* 2011; 8: 75.
- [32] Simone BA, Champ CE, Rosenberg AL et al. Selectively starving cancer cells through dietary manipulation: methods and clinical implications. *Future Oncol* 2013; 9: 959-76.
- [33] F. Di Pierro, R. Settembre. Safety and efficacy of an add-on therapy with curcumin phytosome and piperine and/or lipoic acid in subjects with a diagnosis of peripheral neuropathy treated with dexibuprofen. *J Pain R* 2013; 6: 497-503.
- [34] F. Di Pierro, G. Rapacioli, E. Di Maio, G. Appendino, F. Franceschi, S. Togni. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva), nimesulide, and acetaminophen. *J Pain Res* 2013; 6: 201-205.
- [35] Somlak Chuengsamarn, Suthee Rattanamongkolgul, Rataya Luechapudiporn, Chada Phisalaphong, Siwannon Jirawatnotai. Curcumin Extract for Prevention of Type 2 Diabetes. *Diabetes Care* 2012; 35: 1-7.
- [36] Guo-Xin Hu, Han Lin, Qing-Quan Lian, Shu-Hua Zhou, Jingjing Guo, Hong-Yu Zhou, Yanhui Chu, Ren-Shan Ge. Curcumin as a Potent and Selective Inhibitor of 11 β -Hydroxysteroid Dehydrogenase 1: Improving Lipid Profiles in High-Fat-Diet-Treated Rats. *PLoS One* 2013; 8 (3): e49976.
- [37] Takashi Okura, Michiko Ibe, Keizo Umegaki, Kazumasa Shinozuka, Shizuo Yamada. Effects of Dietary Ingredients on Function and Expression of P-Glycoprotein in Human Intestinal Epithelial Cells. *Biol Pharm Bull* 2010; 33 (2): 255-259.
- [38] Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cucurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. *Oncol Rep* 2008 Oct; 20 (4): 731-5.
- [39] Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm* 2007 Nov-Dec; 4 (6): 807-18.
- [40] Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. *Cancer Epidemiol Biomarkers Prev* 2008 Jun; 17 (6): 1411-7.
- [41] Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends Pharmacol Sci* 2009 Feb; 30 (2): 85-94.
- [42] Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. *Eur J Clin Pharmacol* 1992; 43 (6): 667-9.
- [43] Ernst E. Frankincense: systematic review. *BMJ* 2008 Dec 17; 337: a2813.
- [44] AAVV. *Boswellia serrata*. Monograph. *Altern Med Rev* 2008 Jun; 13 (2): 165-7.
- [45] Donejko M, Niczyporuk M, Galicka E, Przylipiak A. Anti-cancer properties epigallocatechin-gallate contained in green tea. *Postepy Hig Med Dosw* 2013 Jan 16; 67: 26-34.
- [46] Landis-Piwowar K, Chen D, Folds R, Chan TH, Dou QP. Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009-present). *Expert Opin Ther Pat* 2013 Feb; 23 (2): 189-202.
- [47] Khan N, Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. *Biochem Pharmacol* 2013 Mar 1; 85 (5): 667-72.
- [48] Holzapfel NP, Holzapfel BM, Champ S, Feldthusen J, Clements J, Huttmacher DW. The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. *Int J Mol Sci* 2013 Jul 12; 14 (7): 14620-46.
- [49] Sharoni Y, Linnewiel-Hermoni K, Zango G, Khanin M, Salman H, Veprik A, Danilenko M, Levy J. The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention. *Am J Clin Nutr* 2012 Nov; 96 (5): 1173S-8S.
- [50] Story EN, Kopec RE, Schwartz SJ, Harris GK. An update on the health effects of tomato lycopene. *Annu Rev Food Sci Technol* 2010; 1: 189-210.
- [51] Nagata C. Factors to consider in the association between soy isoflavone intake and breast cancer risk. *J Epidemiol* 2010; 20 (2): 83-9.
- [52] Messina M. A brief historical overview of the past two decades of soy and isoflavone research. *J Nutr* 2010 Jul; 140 (7): 1350S-4S.
- [53] Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. *Cancer Metastasis Rev* 2010 Sep; 29 (3): 465-82.
- [54] Zhang Y, Chen H. Genistein, an epigenome modifier during cancer prevention. *Epigenetics* 2011 Jul; 6 (7): 888-91.
- [55] Lee JY, Kim HS, Song YS. Genistein as a Potential Anticancer Agent against Ovarian Cancer. *J Tradit Complement Med* 2012 Apr; 2 (2): 96-104.
- [56] Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. *J Nutr Biochem* 2011 Sep; 22 (9): 799-806.
- [57] Tomczyk J, Olejnik A. Sulforaphane: a possible agent in prevention and therapy of cancer. *Postepy Hig Med Dosw* 2010 Nov 29; 64: 590-604.
- [58] Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. *AAPS J* 2010 Mar; 12(1): 87-97.
- [59] V.S. Govindarajan, Ginger-chemistry, technology, and quality evaluation: part 2. *Critical Reviews in Food Science and Nutrition* 1982; vol. 17, no. 3, 189-258.
- [60] S.D. Jolad, R.C. Lantz, A.M. Solyom, G.J. Chen, R.B. Bates, B.N. Timmermann, Fresh organically grown ginger (*Zingiber officinale*): composition and effects on

- LPS-induced PGE2 production. *Phytochemistry* 2004; vol. 65, no. 13, 1937-1954.
- [61] W.C. Evans, *Ginger. Trease and Evans Pharmacognosy*, 15th edition, WB Saunders, 2002.
- [62] M. O'Hara, D. Kiefer, K. Farrell, K. Kemper, A review of 12 commonly used medicinal herbs. *Archives of Family Medicine* 1998; vol. 7, no. 6, 523-536.
- [63] A.A. Oyagbemi, A.B. Saba, O.I. Azeez, Molecular targets of [6]-gingerol: its potential roles in cancer chemoprevention. *BioFactors* 2010; vol. 36, no. 3, 169-178.
- [64] J. Yamahara, M. Mochizuki, H. Q. Rong, H. Matsuda, H. Fujimura, The anti-ulcer effect in rats of ginger constituents. *Journal of Ethnopharmacology* 1988; vol. 23, no. 2-3, 299-304.
- [65] H. Wu, D. Ye, Y. Bai, Y. Zhao, Effect of dry ginger and roasted ginger on experimental gastric ulcers in rats. *China Journal of Chinese Materia Medica* 1990; vol. 15, no. 5, 278-317.
- [66] M. Thomson, K.K. Al-Qattan, S.M. Al-Sawan, M.A. Alnaqeeb, I. Khan, M. Ali, The use of ginger (*Zingiber officinale* Rosc.) as a potential anti-inflammatory and antithrombotic agent. *Prostaglandins Leukotrienes and Essential Fatty Acids* 2002; vol. 67, no. 6, 475-478.
- [67] G.C. Jagetia, M.S. Baliga, P. Venkatesh, J.N. Ulloor, Influence of ginger rhizome (*Zingiber officinale*) on survival, glutathione and lipid peroxidation in mice after whole-body exposure to Gamma radiation. *Radiation Research* 2003; vol. 160, no. 5, 584-592.
- [68] C. Ficker, M.L. Smith, K. Akpagana et al. Biosay-guided isolation and identification of antifungal compounds from ginger. *Phytotherapy Research* 2003; vol. 17, no. 8, 897-902.
- [69] R. Grzanna, L. Lindmark, C. G. Frondoza, Ginger an herbal medicinal product with broad anti-inflammatory actions. *Journal of Medicinal Food* 2005; vol. 8, no. 2, 125-132.
- [70] J.A.O. Ojewole, Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of *Zingiber officinale* (Roscoe) rhizomes (*Zingiberaceae*) in mice and rats. *Phytotherapy Research* 2006; vol. 20, no. 9, 764-772.
- [71] J.K. Kim, Y. Kim, K.M. Na, Y.J. Surh, T.Y. Kim, [6]-gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. *Free Radical Research* 2007; vol. 41, no. 5, 603-614.
- [72] Z.M. Al-Amin, M. Thomson, K.K. Al-Qattan, M. Ali, Anti-diabetic and hypolipidaemic properties of ginger (*Zingiber officinale*) in streptozotocin-induced diabetic rats. *British Journal of Nutrition* 2006; vol. 96, no. 4, 660-666.
- [73] S.A. Boone, K.M. Shields, Treating pregnancy-related nausea and vomiting with ginger. *Annals of Pharmacotherapy* 2005; vol. 39, no. 10, 1710-1713.
- [74] N. Chaiyakunapruk, N. Kitikannakorn, S. Nathisuwan, K. Leeprakobboon, C. Leelasattagool, The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. *American Journal of Obstetrics and Gynecology* 2006; vol. 194, no. 1, 95-99.
- [75] Z. Iqbal, M. Lateef, M.S. Akhtar, M.N. Ghayur, A.H. Gilani, In vivo anthelmintic activity of ginger against gastrointestinal nematodes of sheep. *Journal of Ethnopharmacology* 2006; vol. 106, no. 2, 285-287.
- [76] Y. Shukla, M. Singh, Cancer preventive properties of ginger: a brief review. *Food and Chemical Toxicology* 2007; vol. 45, no. 5, 683-690.
- [77] Palatty PL, Haniadka R, Valder B, Arora R, Baliga MS. Ginger in the prevention of nausea and vomiting: a review. *Crit Rev Food Sci Nutr* 2013; 53 (7): 659-69.
- [78] Marx WM, Teleni L, McCarthy AL, Vitetta L, McKavanagh D, Thomson D, Isenring E. Ginger (*Zingiber officinale*) and chemotherapy-induced nausea and vomiting: a systematic literature review. *Nutr Rev* 2013 Apr; 71 (4): 245-54.
- [79] Lee J, Oh H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. *Oncol Nurs Forum* 2013 Mar; 40 (2): 163-70. doi: 10.1188/13.ONF.163-170
- [80] Navari RM. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. *Drugs* 2013 Mar; 73 (3): 249-62. doi: 10.1007/s40265-013-0019-1
- [81] Haniadka R, Rajeev AG, Palatty PL, Arora R, Baliga MS. *Zingiber officinale* (ginger) as an anti-emetic in cancer chemotherapy: a review. *J Altern Complement Med* 2012 May; 18 (5): 440-4.
- [82] Guay DR. Cranberry and urinary tract infections. *Drugs* 2009; 69 (7): 775-807.
- [83] Pappas E, Schaich KM. Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability. *Crit Rev Food Sci Nutr* 2009; 49 (9): 741-781.
- [84] Howell AB, Botto H, Combesure C, Blanc-Potard AB, Gausa L. Dosage effect on uropathogenic *Escherichia coli* anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. *BMC Infect Dis* 2010, 14; 10-94.
- [85] Rossi R, Porta S, Canovi B. Overview on cranberry and urinary tract infections in females. *J Clin Gastroenterol* 2010; 44 (Suppl 1): S61-S62.
- [86] Pinzón-Arango PA, Liu Y, Camesano TA. Role of cranberry on bacterial adhesion forces and implications for *Escherichia coli*-uroepithelial cell attachment. *J Med Food* 2009 Apr; 12 (2): 259-70.
- [87] Avorn J, Monane M, Gurwitz JH, Glynn RJ, Chodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. *JAMA* 1994; 271 (10): 751-754.
- [88] Pappas E, Schaich KM. Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability. *Crit Rev Food Sci Nutr* 2009; 49 (9): 741-781.
- [89] Matsushima M, Suzuki T, Masui A, Kasai K, Kouchi T. Growth inhibitory action of cranberry on *Helicobacter pylori*. *J Gastroenterol Hepatol* 2008; 23 (Suppl 2): S175-S180.
- [90] Bonetta A, Di Pierro F. Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma. *Cancer Manag Res* 2012; 4: 281-6.
- [91] Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on

- prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. *Hepatogastroenterology* 1999 Jul-Aug; 46 (28): 2662-8.
- [92] Bisen PS, Baghel RK, Sanodiya BS, Thakur GS, Prasad GB. Lentinus edodes: a macrofungus with pharmacological activities. *Curr Med Chem* 2010; 17 (22): 2419-30.
- [93] Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, Nakazawa S et al. Efficacy of orally administered superfine dispersed lentinan (β -1,3-glucan) for the treatment of advanced colorectal cancer. *Anticancer Res* 2009 Jul; 29 (7): 2611-7.
- [94] Nicolini A, Ferrari P, Masoni MC, Fini M, Pagani S, Giampietro O, Carpi A. Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. *Biomed Pharmacother* 2013 Oct; 67 (8): 807-17.
- [95] Berardi E, Annibali D, Cassano M, Crippa S, Sampaolesi M. Molecular and cell-based therapies for muscle degenerations: a road under construction. *Front Physiol* 2014 Apr 8; 5: 119.
- [96] Jenkinson C, Petroczi A, Naughton DP. Red wine and component flavonoids inhibit UGT2B17 in vitro. *Nutr J* 2012 Sep 7; 11: 67. doi:10.1186/1475-2891-11-67
- [97] Blau JN, Kell CA, Sperling JM. Water-deprivation headache: a new headache with two variants. *Headache* 2004 Jan; 44 (1): 79-83.
- [98] <http://healthcentral.com/migraine/triggers-39683-5.html>
- [99] Jes Olesen, Peter J. Goadsby, Nabih M. Ramadan, Peer Tfelt-Hansen, K. Michael A. Welch, *The Headaches*, 3rd edition, Lippincott Williams & Wilkins, 2005.
- [100] Morris Levin, Steven M. Baskin, Marcelo E. Bigal, *Comprehensive Review of Headache Medicine*, Oxford University Press US, 2008.
- [101] Orr SL, Venkateswaran S. Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations. *Cephalalgia* 2014 Feb 24.
- [102] Allais G, D'Andrea G, Maggio M, Benedetto C. The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. *Neurol Sci* 2013 May; 34 Suppl 1: S161-3.
- [103] Carotenuto M, Esposito M. Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I. *Neurol Sci* 2013 Nov; 34 (11): 1905-9.
- [104] Singh P, Singh IN, Mondal SC, Singh L, Garg VK. Platelet-activating factor (PAF)-antagonists of natural origin. *Fitoterapia* 2013 Jan; 84: 180-201.
- [105] Saracco MG, Calabrese G, Cavallini M, Montano V, Rinaldi B, Valfrè W, Aguggia M. Relationship between primary headache and nutrition: a questionnaire about dietary habits of patients with headache. *Neurol Sci* 2014 May; 35 Suppl 1: 159-61.
- [106] Krymchantowski AV, da Cunha Jevoux C. Wine and Headache. *Headache* 2014 May 6.
- [107] Orenstein SB, Marks JM, Hardacre JM. Technical aspects of bile duct evaluation and exploration. *Surg Clin North Am* 2014 Apr; 94 (2): 281-96.
- [108] Cafasso DE, Smith RR. Symptomatic cholelithiasis and functional disorders of the biliary tract. *Surg Clin North Am* 2014 Apr; 94 (2): 233-56.
- [109] Schirmer BD, Winters KL, Edlich RF. Cholelithiasis and cholecystitis. *J Long Term Eff Med Implants* 2005; 15 (3): 329-38.
- [110] Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. *World J Hepatol* 2012 Feb 27; 4 (2): 18-34.
- [111] O'Brien P, Carrasco-Pozo C, Speisky H. Boldine and its antioxidant or health-promoting properties. *Chem Biol Interact* 2006 Jan 5; 159 (1): 1-17.
- [112] Speisky H, Cassels BK. Boldo and boldine: an emerging case of natural drug development. *Pharmacol Res* 1994 Jan-Feb; 29 (1): 1-12.
- [113] Yu B, Cook C, Santanam N. The aporphine alkaloid boldine induces adiponectin expression and regulation in 3T3-L1 cells. *J Med Food* 2009 Oct; 12 (5): 1074-83.
- [114] Gotteland M, Espinoza J, Cassels B, Speisky H. Effect of a dry boldo extract on oro-cecal intestinal transit in healthy volunteers. *Rev Med Chil* 1995 Aug; 123 (8): 955-60.
- [115] Wegener T, Fintelmann V. Pharmacological properties and therapeutic profile of artichoke (*Cynara scolymus* L.). *Wien Med Wochenschr* 1999; 149 (8-10): 241-7.
- [116] Thompson Coon JS, Ernst E. Herbs for serum cholesterol reduction: a systematic view. *J Fam Pract* 2003 Jun; 52 (6): 468-78.
- [117] Wegener T. The status of herbal antilipemic agent. *Wien Med Wochenschr* 2002; 152 (15-16): 412-7.
- [118] Riggs BL, Melton LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. 3rd. *Bone* 1995 Nov; 17 (5 Suppl): 505S-511S.
- [119] Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. *Am J Obstet Gynecol* 2006 Feb; 194 (2 Suppl): S3-11.
- [120] Gerdhem P. Osteoporosis and fragility fractures. *Best Pract Res Clin Rheumatol* 2013 Dec; 27 (6): 743-755.
- [121] Ebeling PR. Vitamin D and bone health: epidemiologic studies. *Bonekey Rep* 2014 Mar 5; 3: 511.
- [122] Langsetmo L, Berger C, Kreiger N, Kovacs CS, Hanley DA, Jamal SA, Whiting SJ, Genest J, Morin SN, Hodsman A et al. Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). *J Clin Endocrinol Metab* 2013 Jul; 98 (7): 3010-8.
- [123] Quesada Gómez JM, Blanch Rubió J, Díaz Curiel M, Díez Pérez A. Calcium citrate and vitamin D in the treatment of osteoporosis. *Clin Drug Investig* 2011; 31 (5): 285-98.
- [124] http://salute.gov.it/imgs/C_17_pagineAree_1464_listaFile_itemName_0_file.pdf
- [125] J. Compston, C. Bowring, A. Cooper, C. Cooper, C. Davies, R. Francis, J.A. Kanis, D. Marsh, E.V. McCloskey, D.M. Reid, P. Selby, National Osteoporosis Guideline Group (NOGG). Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: update 2013. *Maturitas* August 2013; Volume 75, Issue 4, 392-396.
- [126] Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 2010; 341: c3691.
- [127] Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and

- risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ* 2011; 342: d2040.
- [128] Abrahamsen B, Sahota O. Do calcium plus vitamin D supplements increase cardiovascular risk? *BMJ* 2011; 342: d2080.
- [129] Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. *Maturitas* 2013 Sep; 76 (1): 10-21.
- [130] Cosman F. Combination therapy for osteoporosis: a reappraisal. *Bonekey Rep* 2014 Apr 2; 3: 518.
- [131] Lagari VS, Levis S. Phytoestrogens in the prevention of postmenopausal bone loss. *J Clin Densitom* 2013 Oct-Dec; 16 (4): 445-9.
- [132] Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O. Soy isoflavones in the management of postmenopausal osteoporosis. *Menopause* 2008 Jul-Aug; 15 (4 Pt 1): 748-57.
- [133] Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. *J Steroid Biochem Mol Biol* 2014 Jan; 139: 225-36.
- [134] Lagari VS, Levis S. Phytoestrogens for menopausal bone loss and climacteric symptoms. *J Steroid Biochem Mol Biol* 2014 Jan; 139: 294-301.
- [135] Park CY, Weaver CM. Vitamin D interactions with soy isoflavones on bone after menopause: a review. *Nutrients* 2012 Nov 6; 4 (11): 1610-21.
- [136] Sacco SM, Horcajada MN, Offord E. Phytonutrients for bone health during ageing. *Br J Clin Pharmacol* 2013 Mar; 75 (3): 697-707.
- [137] Liu W, Wang Y, Yang J. Black cohosh (*Cimicifuga species*) for menopausal symptoms. *Clin Nurse Spec* 2013 Nov-Dec; 27 (6): 289-90.
- [138] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013 Jan; 62 (1): 102-11.
- [139] Glasbrenner B, Adler G. Pathophysiology of acute pancreatitis. *Hepatogastroenterology* 1993 Dec; 40 (6): 517-21.
- [140] Tenner S, Baillie J, DeWitt J, Vege SS, American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 2013 Sep; 108 (9): 1400-15; 1416.
- [141] Seicean A, Tantău M, Grigorescu M, Mocan T, Seicean R, Pop T. Mortality risk factors in chronic pancreatitis. *J Gastrointest Liver Dis* 2006 Mar; 15 (1): 21-6.
- [142] Sarles H. Chronic pancreatitis and diabetes. *Baillieres Clin Endocrinol Metab* 1992 Oct; 6 (4): 745-75.
- [143] Liao Z, Jin G, Cai D, Sun X, Hu B, Wang X, Yang Y, Li Y, Xu Z, Ren X, Jin D, Wang C, Li Z. Guidelines: diagnosis and therapy for chronic pancreatitis. *J Interv Gastroenterol* 2013 Oct; 3 (4): 133-136.
- [144] Maev IV, Kucheriawiy IuA. Modern approaches to diagnostics and treatment of chronic pancreatitis. *Klin Med (Mosk)* 2013; 91 (9): 10-6.
- [145] Löhr JM, Haas SL, Lindgren F, Enochsson L, Hedström A, Swahn E, Segersvärd R, Arnelo U. Conservative treatment of chronic pancreatitis. *Dig Dis* 2013; 31 (1): 43-50.
- [146] Zhang XP, Liu DR, Shi Y. Study progress in therapeutic effects of traditional Chinese medicine monomer in severe acute pancreatitis. *J Zhejiang Univ Sci B* 2007 Feb; 8 (2): 147-52.
- [147] Zhu L, Zhao JL, Peng XH, Wan MH, Huang X, Tang WF. Pharmacological study on free anthraquinones compounds in rhubarb in rats with experimental acute pancreatitis. *Zhongguo Zhong Yao Za Zhi* 2014 Jan; 39 (2): 304-8.
- [148] Zheng SH, Tong QY, Zhu ZY, Li ZY, You H. Effect of rhubarb administered via different routes on blood inflammatory cytokines levels of patients with severe acute pancreatitis. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue* 2011 Jul; 23 (7): 437-8.
- [149] Zhao YQ, Liu XH, Ito T, Qian JM. Protective effects of rhubarb on experimental severe acute pancreatitis. *World J Gastroenterol* 2004 Apr 1; 10 (7): 1005-9.
- [150] Qin Y, Wang JB, Kong WJ, Zhao YL, Yang HY, Dai CM, Fang F, Zhang L, Li BC, Jin C, Xiao XH. The diarrhoeogenic and anti-diarrhoeal bidirectional effects of rhubarb and its potential mechanism. *J Ethnopharmacol* 2011 Feb 16; 133 (3): 1096-102.
- [151] Peng GL, Zhang XY. Effects of *Salvia miltiorrhiza* on serum levels of inflammatory cytokines in patients with severe acute pancreatitis. *Zhong Xi Yi Jie He Xue Bao* 2007 Jan; 5 (1): 28-31.
- [152] Zhang XP, Li ZJ, Liu DR. Progress in research into the mechanism of *Radix salviae miltiorrhizae* in treatment of acute pancreatitis. *Hepatobiliary Pancreat Dis Int* 2006 Nov; 5 (4): 501-4.
- [153] Ou JM, Zhang XP, Wu CJ, Wu DJ, Yan P. Effects of dexamethasone and *Salvia miltiorrhiza* on multiple organs in rats with severe acute pancreatitis. *J Zhejiang Univ Sci B* 2012 Nov; 13 (11): 919-31.
- [154] Gulcubuk A, Haktanir D, Cakiris A, Ustek D, Guzel O, Erturk M, Yildirim F, Akyazi I, Cicekci H, Durak MH, Sandikci-Altunatmaz S, Altunatmaz K. The effects of resveratrol on tissue injury, oxidative damage, and pro-inflammatory cytokines in an experimental model of acute pancreatitis. *J Physiol Biochem* 2014 Jun; 70 (2): 397-406.
- [155] Carrasco C, Holguín-Arévalo MS, Martín-Partido G, Rodríguez AB, Pariente JA. Chemopreventive effects of resveratrol in a rat model of cerulein-induced acute pancreatitis. *Mol Cell Biochem* 2014 Feb; 387 (1-2): 217-25.
- [156] Acute Viral Hepatitis: Introduction *Harrison's Principle of Internal Medicine*, 17th edition, McGraw-Hill Medical, 2008.
- [157] Chronic hepatitis in: *Merck Manual of Diagnosis and Therapy*, Home Edition.
- [158] Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. *Eur J Clin Pharmacol* 1992; 43 (6): 667-9.
- [159] Sales I, Dzierba AL, Smithburger PL, Rowe D, Kane-Gill SL. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. *Ann Hepatol* 2013 Jan-Feb; 12 (1): 6-10.
- [160] Amathieu R, Levesque E, Merle JC, Chemit M, Costentin C, Compagnon P, Dhonneur G. Severe toxic acute liver failure: etiology and treatment. *Ann Fr Anesth Reanim* 2013 Jun; 32 (6): 416-21.

- [161] Pensalfini A, Cecchi C, Zampagni M, Becatti M, Favilli F, Paoli P, Catarzi S, Bagnoli S, Nacmias B, Sorbi S, Liguri G. Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress. *Free Radic Biol Med* 2008 Apr 15; 44 (8): 1624-36.
- [162] Di Pierro F, Rossoni G. An Amino Acids Mixture Improves the Hepatotoxicity Induced by Acetaminophen in Mice. *J Amino Acids* 2013, ID 615754: 1-6.
- [163] Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. *Ann Hepatol* 2013 Mar-Apr; 12 (2): 183-9.
- [164] Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. *J Appl Toxicol* 2008 Mar; 28 (2): 93-103.
- [165] Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. *BioDrugs* 2001; 15 (7): 465-89.
- [166] Kidd PM. Bioavailability and activity of phyto-some complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. *Altern Med Rev* 2009 Sep; 14 (3): 226-46.
- [167] Di Pierro F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue. *Acta Biomed* 2008 Dec; 79 (3): 205-10.
- [168] Leung L, Riutta T, Kotecha J, Rosser W. Chronic constipation: an evidence-based review. *J Am Board Fam Med* 2011 Jul-Aug; 24 (4): 436-51.
- [169] de Witte P, Lemli L. The metabolism of anthranoid laxatives. *Hepatogastroenterology* 1990 Dec; 37 (6): 601-5.
- [170] Borrelli F, Aviello G, Capasso R, Capasso F. Senna: a laxative devoid of carcinogenic effects. *Arch Toxicol* 2006 Dec; 80 (12): 873.
- [171] Nusko G, Schneider B, Ernst H, Wittekind C, Hahn EG. Melanosis coli: a harmless pigmentation or a precancerous condition? *Z Gastroenterol* 1997 May; 35 (5): 313-8.
- [172] Di Pierro F, Rapacioli G, Callegari A, Attolico M, Ivaldi L, Candidi C. Efficacia clinica nella stipsi di un preparato a base di antrachinoni e oli essenziali: effetto lassativo concomitante ad azione antinfiammatoria. *Il Gastroenterologo* 2009; Anno XXXI, n. 1-2: 13-19.
- [173] Johanson JF. Review of the treatment options for chronic constipation. *MedGenMed* 2007 May 2; 9 (2): 25.
- [174] Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. *Am J Gastroenterol* 2005 Apr; 100 (4): 936-71.
- [175] Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. *J Clin Pharm Ther* 2011 Jun; 36 (3): 275-82.
- [176] Slavin J. Fiber and prebiotics: mechanisms and health benefits. *Nutrients* 2013 Apr 22; 5 (4): 1417-35.
- [177] Bradshaw DJ, Lynch RJ. Diet and the microbial aetiology of dental caries: new paradigms. *Int Dent J* 2013 Dec; 63 Suppl 2: 64-72.
- [178] Caufield PW, Li Y, Dasanayake A. Dental caries: an infectious and transmissible disease. *Compend Contin Educ Dent* 2005 May; 26 (5 Suppl 1): 10-6.
- [179] Perumal E, Paul V, Govindarajan V, Panneerselvam L. A brief review on experimental fluorosis. *Toxicol Lett* 2013 Nov 25; 223 (2): 236-51.
- [180] Tubert-Jeannin S, Auclair C, Amsallem E, Trami-ni P, Gerbaud L, Ruffieux C, Schulte AG, Koch MJ, Règ-e-Walther M, Ismail A. Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children. *Cochrane Database Syst Rev* 2011 Dec 7; (12): CD007592.
- [181] Kuramitsu HK, Wang BY. The whole is greater than the sum of its parts: dental plaque bacterial interactions can affect the virulence properties of cariogenic *Streptococcus mutans*. *Am J Dent* 2011 Jun; 24 (3): 153-4.
- [182] Mosci F, Perito S, Bassa S, Capuano A, Marconi PF. The role of *Streptococcus mutans* in human caries. *Minnerva Stomatol* 1990 May; 39 (5): 413-29.
- [183] Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of *Streptococcus salivarius* K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. *Drug Health Patient Saf* 2014 Feb 13; 6: 15-20.
- [184] Burton JP, Wescombe PA, Macklaim JM, Chai MH, Macdonald K, Hale JD, Tagg J, Reid G, Gloor GB, Cadieux PA. Persistence of the oral probiotic *Streptococcus salivarius* M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics. *PLoS One* 2013 Jun 13; 8 (6): e65991.
- [185] Burton JP, Drummond BK, Chilcott CN, Tagg JR, Thomson WM, Hale JD, Wescombe PA. Influence of the probiotic *Streptococcus salivarius* strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. *J Med Microbiol* 2013 Jun; 62 (Pt 6): 875-84. doi: 10.1099/jmm.0.056663-0. Epub 2013 Feb 28.
- [186] Heng NC, Haji-Ishak NS, Kalyan A, Wong AY, Lovric M, Bridson JM, Artamonova J, Stanton JA, Wescombe PA, Burton JP, Cullinan MP, Tagg JR. Genome sequence of the bacteriocin-producing oral probiotic *Streptococcus salivarius* strain M18. *J Bacteriol* 2011 Nov; 193 (22): 6402-3.